US SB1276 | 2017-2018 | 115th Congress
Status
Spectrum: Slight Partisan Bill (Democrat 5-3)
Status: Introduced on May 25 2017 - 25% progression, died in committee
Action: 2017-05-25 - Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S3220-3221)
Pending: Senate Judiciary Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on May 25 2017 - 25% progression, died in committee
Action: 2017-05-25 - Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S3220-3221)
Pending: Senate Judiciary Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Cannabidiol Research Expansion Act This bill requires the Drug Enforcement Administration (DEA) and the Department of Health and Human Services to each evaluate whether cannabidiol, the nonpsychoactive substance derived from marijuana or the synthetic formulation, should be a controlled substance under the Controlled Substances Act. After taking into consideration the evaluations, the DEA must initiate proceedings for classifying cannabidiol as a controlled substance if control is warranted. The bill expands the authority for: (1) conducting medical research on cannabidiol and other nonpsychoactive components of marijuana, and (2) possessing or transporting cannabidiol or any other nonpsychoactive component of marijuana for certain medicinal purposes. The Department of Justice shall register an applicant to manufacture or distribute cannabidiol or marijuana for the purpose of commercial production if approved by HHS. Physicians who are licensed under state law may discuss the potential harms and benefits of cannabidiol or those components of marijuana as a treatment with their patients or the legal guardians of underage patients. The bill terminates four years after enactment.
Title
Cannabidiol Research Expansion Act
Sponsors
Sen. Dianne Feinstein [D-CA] | Sen. Chuck Grassley [R-IA] | Sen. Richard Durbin [D-IL] | Sen. Thom Tillis [R-NC] |
Sen. Joni Ernst [R-IA] | Sen. Sheldon Whitehouse [D-RI] | Sen. Tim Kaine [D-VA] | Sen. Amy Klobuchar [D-MN] |
History
Date | Chamber | Action |
---|---|---|
2017-05-25 | Senate | Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S3220-3221) |
Subjects
Alternative treatments
Child health
Crime and law enforcement
Drug therapy
Drug trafficking and controlled substances
Education programs funding
Government studies and investigations
Health personnel
Health programs administration and funding
Higher education
Licensing and registrations
Medical education
Medical research
Neurological disorders
Research administration and funding
Trade restrictions
Child health
Crime and law enforcement
Drug therapy
Drug trafficking and controlled substances
Education programs funding
Government studies and investigations
Health personnel
Health programs administration and funding
Higher education
Licensing and registrations
Medical education
Medical research
Neurological disorders
Research administration and funding
Trade restrictions
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/115th-congress/senate-bill/1276/all-info |
Text | https://www.congress.gov/115/bills/s1276/BILLS-115s1276is.pdf |